Feb 24, 2026 · What to know CDC recommends a single dose of respiratory syncytial virus (RSV) vaccine for all adults ages 75 and older and adults ages 50–74 at increased risk of severe RSV …

Sep 19, 2023 · Two respiratory syncytial virus (RSV) vaccines are coming to the market nearly 60 years after the National Institutes of Health first attempted to develop one. In May 2023, pharmaceutical …

Today, the U.S. Food and Drug Administration approved Arexvy, the first respiratory syncytial virus (RSV) vaccine approved for use in the United States. Arexvy is approved for the prevention of...

May 1, 2025 · Characterizing the safety and effectiveness of recently introduced vaccines against RSV is critical. Objective: To assess the safety and effectiveness of vaccines against RSV and the major …

Aug 6, 2024 · The FDA approved the first-ever RSV vaccine in May 2023. The shot, called Arexvy and made by the pharmaceutical company GSK, is approved for adults ages 60 and older.

May 9, 2025 · The authors noted that updated RSV vaccine safety analyses among adults aged 60 years or older, including results from the full 2023-2024 RSV season, are needed to confirm these …

Dec 13, 2023 · Respiratory syncytial virus (RSV) can cause substantial morbidity and mortality among older adults. An mRNA-based RSV vaccine, mRNA-1345, encoding the stabilized RSV prefusion F...

Sep 1, 2024 · In 2023 and 2024, 3 vaccines were approved by the US Food and Drug Administration (FDA) against respiratory syncytial virus (RSV) in adults. In addition, the first long-acting RSV …

RSV Vaccines Efficacy and safety In June 2023, CDC’s Advisory Committee on Immunization Practices (ACIP) recommended the first two RSV vaccines for older adults.

Jan 3, 2025 · What RSV vaccines are available for adults? The first vaccines for RSV were licensed by the Food and Drug Administration (FDA) in 2023 for older adults. There are now three RSV vaccines …